← Eichor
Condition: Allogenic Bone Marrow Transplantation Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Allogenic Bone Marrow Transplantation

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Phase 1/3 Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Ce
Phase 1 · 21 location(s) · TScan Therapeutics, Inc. · NCT05473910Thiotepa-Containing Conditioning Regimen for Allogeneic HSCT in Chronic Myelomonocytic Leukemia
NA · 1 location(s) · Peking University People's Hospital · NCT07588594Methods of T Cell Depletion Trial (MoTD)
Phase 2 · 17 location(s) · University of Birmingham · NCT04888741The HOPE Biobank Resource (BMT CTN 2402 HOPE)
Phase N/A · 6 location(s) · Medical College of Wisconsin · NCT07227155oGVHD After Bone Marrow Transplantation: a Territory-wide Cohort
Phase N/A · 1 location(s) · The University of Hong Kong · NCT05170347AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion
Phase 2 · 1 location(s) · Mitchell Cairo · NCT04099966Molecular Mechanisms of Disease Relapse After Allogenic Stem Cell Transplantation in MDS Patients
NA · 7 location(s) · Gruppo Italiano Malattie EMatologiche dell'Adulto · NCT04587856Momelotinib During and After HCT in Myelofibrosis
Phase 1 · 1 location(s) · Massachusetts General Hospital · NCT07104799Trial for Patients w/ Advanced Hematologic Malignancies Undergoing Allogeneic HCT
Phase 1 · 1 location(s) · Stanford University · NCT06551584Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Foll
Phase 1/Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT05470491Vitamin A and D Supplementation in Allogeneic HCT
Phase 2 · 1 location(s) · St. Petersburg State Pavlov Medical University · NCT06508099Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versu
Phase 1 · 1 location(s) · City of Hope Medical Center · NCT06996119Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
Phase 2 · 1 location(s) · Masonic Cancer Center, University of Minnesota · NCT03314974Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing
Phase N/A · 1 location(s) · National Cancer Institute (NCI) · NCT06856226MAGIC Ruxolitinib for aGVHD
Phase 2 · 14 location(s) · John Levine · NCT06936566CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relap
Phase 1 · 1 location(s) · Fred Hutchinson Cancer Center · NCT04375631211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymph
Phase 1/Phase 2 · 1 location(s) · Fred Hutchinson Cancer Center · NCT03128034CD7 CAR-T Bridging to alloHSCT for Severe Aplastic Anemia
EARLY_Phase 1 · 1 location(s) · Zhejiang University · NCT06633328MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludara
Phase 2 · 1 location(s) · Masonic Cancer Center, University of Minnesota · NCT07493538Trial of 2 Step ATG for Prevention of Acute GVHD Post Allogeneic Stem Cell Transplant
Phase 2 · 1 location(s) · University of Alabama at Birmingham · NCT06265584Faecal Microbiota Transplantation After Allogeneic Stem Cell Transplantation
Phase 2 · 20 location(s) · University Hospital, Clermont-Ferrand · NCT04935684The MedMemos Study: Promoting Adherence to Medications in Pediatric Bone Marrow Transplant Patients
NA · 1 location(s) · Nationwide Children's Hospital · NCT07718204Anti-NKG2A Monoclonal Antibody for AML or MDS Patients Undergoing Haploidentical Transplantation
Phase 2 · 2 location(s) · Istituto Clinico Humanitas · NCT06892223Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant
Phase 1 · 2 location(s) · City of Hope Medical Center · NCT06543381High-Altitude Hematology Observation-Stem Cell Transplantation (HALO-SCT)
Phase N/A · 1 location(s) · Yigeng Cao,MD,PhD · NCT07205523Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant
Phase 1/Phase 2 · 1 location(s) · Fred Hutchinson Cancer Center · NCT06928662A Study Using Subject-specific MRD to Adopt Treatment After HSCT for Subjects With MDS
Phase 2 · 1 location(s) · Karolinska University Hospital · NCT05788679Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-inten
Phase 2 · 10 location(s) · University of Liege · NCT03852407Rehab Study for alloBMT Patients
NA · 1 location(s) · Jennifer Jones · NCT07457866Genetics in the Progression of Nephropathies
Phase N/A · 1 location(s) · Ospedale San Raffaele · NCT06416761
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.